COVID-19 rapid guideline: cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
GINA strategy 2020: assessing patients with asthma
This Guidelines summary outlines recommendations for assessing patients with asthma. Please refer to the full report for the complete set of recommendations.
GINA strategy 2020: asthma–COPD overlap
This Guidelines summary outlines recommendations for the diagnosis and initial treatment of adults with features of asthma, chronic obstructive pulmonary disease (COPD), or both.
GINA strategy 2020: management of asthma
This Guidelines summary outlines recommendations for the management of asthma in adults, adolescents, and children aged six to 11.
GINA strategy 2020: diagnosis of asthma
This Guidelines summary outlines recommendations for making the diagnosis of asthma in adults and children over five years of age. Please refer to the full report for the complete set of recommendations.
COVID-19 rapid guideline: pneumonia in adults
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic.
COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)
The purpose of this summary is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources. For more detailed information, please refer to the full guideline.
COVID-19 rapid guideline: severe asthma
The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
Resource hub
Inhaler standards and competency document
- Previous
- Next
Educational resources
COPD: LAMA/LABA therapy—Real life case studies
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200015
COPD: LAMA/LABA as initial maintenance therapy for appropriate symptomatic patients
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200014
Why you might want to review patients with COPD receiving a LAMA
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200013
COPD: Have you done enough to implement guidelines?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200012
Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?
This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200011